SUMO2 and cardiac hypertrophy: In conclusion, based on an unbiased screening approach, we linked SUMO2 to increased NFAT-activation, induction of hypertrophy-associated genes, and increased cellular and cardiac hypertrophy, both, in vitro and in vivo.